| Primary |
| Local Anaesthesia |
22.1% |
| Anaesthesia |
19.3% |
| Post Herpetic Neuralgia |
5.7% |
| Nerve Block |
5.3% |
| Epidural Anaesthesia |
5.2% |
| Cataract Operation |
4.7% |
| Neuralgia |
4.7% |
| Preoperative Care |
4.6% |
| Pain |
3.6% |
| Drug Use For Unknown Indication |
3.3% |
| Analgesic Therapy |
2.8% |
| General Anaesthesia |
2.8% |
| Induction Of Anaesthesia |
2.6% |
| Product Used For Unknown Indication |
2.4% |
| Hypertension |
2.3% |
| Postoperative Care |
2.1% |
| Eye Irrigation |
1.8% |
| Premedication |
1.7% |
| Ventricular Tachycardia |
1.6% |
| Maintenance Of Anaesthesia |
1.4% |
|
| Anaphylactic Shock |
13.7% |
| Toxicity To Various Agents |
10.8% |
| Overdose |
8.0% |
| Toxic Anterior Segment Syndrome |
5.1% |
| Anaphylactic Reaction |
4.8% |
| Methaemoglobinaemia |
4.8% |
| Vomiting |
4.8% |
| Product Quality Issue |
4.6% |
| Syncope |
4.6% |
| Drug Toxicity |
4.3% |
| Convulsion |
4.0% |
| Drug Ineffective |
4.0% |
| Loss Of Consciousness |
3.7% |
| Off Label Use |
3.7% |
| Speech Disorder |
3.7% |
| Urticaria |
3.7% |
| Dyspnoea |
3.1% |
| Grand Mal Convulsion |
3.1% |
| Unresponsive To Stimuli |
2.8% |
| Neurotoxicity |
2.6% |
|
| Secondary |
| Product Used For Unknown Indication |
25.9% |
| Drug Use For Unknown Indication |
12.5% |
| Anaesthesia |
8.7% |
| Drug Abuse |
6.6% |
| Pain |
6.5% |
| Local Anaesthesia |
5.0% |
| Hypertension |
4.0% |
| Arthrogram |
3.8% |
| General Anaesthesia |
3.4% |
| Cataract Operation |
3.0% |
| Preoperative Care |
2.9% |
| Induction Of Anaesthesia |
2.2% |
| X-ray |
2.1% |
| X-ray Limb |
2.1% |
| Nerve Block |
2.0% |
| Epidural Anaesthesia |
2.0% |
| Postoperative Care |
2.0% |
| Maintenance Of Anaesthesia |
1.9% |
| Convulsion |
1.7% |
| Arthralgia |
1.6% |
|
| Septic Arthritis Staphylococcal |
10.0% |
| Wrong Technique In Drug Usage Process |
8.8% |
| Toxic Anterior Segment Syndrome |
6.8% |
| Tachycardia |
6.4% |
| Vomiting |
6.4% |
| Pyrexia |
6.1% |
| Toxicity To Various Agents |
5.6% |
| Ventricular Tachycardia |
5.4% |
| Visual Acuity Reduced |
5.1% |
| Urticaria |
4.6% |
| Weight Decreased |
4.6% |
| Methaemoglobinaemia |
3.9% |
| Unresponsive To Stimuli |
3.9% |
| Anaphylactic Reaction |
3.7% |
| Drug Ineffective |
3.4% |
| Overdose |
3.2% |
| Pain |
3.2% |
| Respiratory Arrest |
3.2% |
| Drug Toxicity |
2.9% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
2.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
38.9% |
| Drug Use For Unknown Indication |
17.6% |
| Pain |
7.0% |
| Prophylaxis |
6.2% |
| Maintenance Of Anaesthesia |
3.6% |
| Coronary Artery Bypass |
2.5% |
| Hypertension |
2.5% |
| Nausea |
2.4% |
| Induction Of Anaesthesia |
2.3% |
| Multiple Myeloma |
1.9% |
| Constipation |
1.9% |
| Non-small Cell Lung Cancer |
1.8% |
| Anaesthesia |
1.7% |
| Arrhythmia |
1.7% |
| Surgery |
1.6% |
| Laryngospasm |
1.5% |
| Depression |
1.4% |
| Anxiety |
1.2% |
| Back Pain |
1.2% |
| Gastrooesophageal Reflux Disease |
1.2% |
|
| Pneumonia |
12.2% |
| Vomiting |
9.8% |
| Pain |
8.6% |
| Unwanted Awareness During Anaesthesia |
7.3% |
| Weight Decreased |
7.0% |
| Weight Increased |
6.0% |
| Injury |
5.8% |
| Death |
4.2% |
| Unevaluable Event |
4.2% |
| Fear |
4.0% |
| Renal Failure |
4.0% |
| Hypoxia |
3.8% |
| Anxiety |
3.5% |
| Drug Ineffective |
2.9% |
| Renal Failure Acute |
2.9% |
| Emotional Distress |
2.8% |
| Ventricular Tachycardia |
2.8% |
| White Blood Cell Count Increased |
2.7% |
| Thrombocytopenia |
2.7% |
| Vision Blurred |
2.7% |
|
| Interacting |
| Arrhythmia |
16.7% |
| Anaesthesia |
13.5% |
| Product Used For Unknown Indication |
12.0% |
| Torsade De Pointes |
8.3% |
| Local Anaesthesia |
7.3% |
| Induction Of Anaesthesia |
5.2% |
| Maternal Exposure During Pregnancy |
5.2% |
| Maintenance Of Anaesthesia |
4.7% |
| Ill-defined Disorder |
4.2% |
| Dental Care |
3.1% |
| Ventricular Tachycardia |
3.1% |
| Anxiety |
2.6% |
| Application Site Anaesthesia |
2.6% |
| Foetal Exposure During Pregnancy |
2.6% |
| Atrial Fibrillation |
2.1% |
| Hypertrophic Cardiomyopathy |
2.1% |
| Tachycardia |
1.6% |
| Abdominal Pain Upper |
1.0% |
| Antiretroviral Therapy |
1.0% |
| Dizziness |
1.0% |
|
| Drug Interaction |
18.6% |
| Tachycardia |
9.3% |
| Ventricular Arrhythmia |
9.3% |
| Mental Status Changes |
7.0% |
| Speech Disorder |
7.0% |
| Disorientation |
4.7% |
| Eructation |
4.7% |
| Miosis |
4.7% |
| Myoclonic Epilepsy |
4.7% |
| Supraventricular Extrasystoles |
4.7% |
| Toxicity To Various Agents |
4.7% |
| Antipsychotic Drug Level Increased |
2.3% |
| Apgar Score Low |
2.3% |
| Chills |
2.3% |
| Choking Sensation |
2.3% |
| Dental Caries |
2.3% |
| Dizziness |
2.3% |
| Dysarthria |
2.3% |
| Dyskinesia |
2.3% |
| Endometrial Cancer |
2.3% |
|
